Small Molecules

Home | Small Molecules | Discovery | Structural Biology

Structural Biology

At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs. Partnering with Curia means you’re not just getting a deliverable—you’re accessing a wealth of knowledge that can make a real difference in your protein expression, structural biology, or Structure-Based Drug Development (SBDD) programs.

Structural Biology Services

We collaborate with you to design a pathway to success, whether you need support with a single step or a complete, end-to-end solution.

 Our expertise includes:

  • Multi-subunit protein complexes
  • Protein nucleic acid complexes
  • Protein-ligand complexes
  • Membrane proteins
  • Structure-Based Drug Development

Unlock the potential of your projects with Curia’s comprehensive solutions in protein chemistry and structural biology services.

Publications

With 100+ publications in peer reviewed journals including Science, Nature Structural and Molecular Biology and The Journal of Medicinal Chemistry. Examples of the range and quality of our protein scientists contributions to research can be found in our list of publications here.

Structural Biology Publications

Protein Chemistry Publications

  • Stokes ME, Surman MD, Calvo V, Surguladze D, Li A-H, Gasparek J, Betzenhauser M, Zhu G, Du H, Rigby AC, Mulvihill MJ (2022) “Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors”, Pharmaceutics, 14(10):2233. doi: 10.3390/pharmaceutics14102233.
  • Calvo V, Surguladze D, Li AH, Surman MD, Malibhatla S, Bandaru M, Jonnalagadda SK, Adarasandi R, Velmala M, Singireddi DRP, Velpuri M, Nareddy BR, Sastry V, Mandati C, Guguloth R, Siddiqui S, Patil BS, Chad E, Wolfley J, Gasparek J, Feldman K, Betzenhauser M, Wiens B, Koszelak-Rosenblum M, Zhu G, Du H, Rigby AC, Mulvihill MJ. (2021) “Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors”, Bioorg Med Chem Lett, 43:128058
  • Karim Md F, Liu S, Laciak AR, Volk L, Koszelak-Rosenblum M, Liber MR, Wu M, Curtis R, Huang NN, Carr G, Zhu G. (2020) “Structural analysis of the catalytic domain of Artemis endonuclease/SNM1C reveals distinct structural features”, J Biol Chem, 295(35):12368-77.
  • Wu, H-Y, Zheng Y, Laciak A, Huang NN, Koszelak-Rosenblum M, Flint AJ, Carr G, Zhu G (2022) “Structure and Function of SNM1 Family Nucleases”, Adv Exp Med Biol – Protein Reviews https://doi.org/10.1007/5584_2022_724  
  • Luo Q, Yang X, Yu S, Shi H, Wang K, Xiao L, Zhu G, Sun C, Li T, Li D, Zhang X, Zhou M, Huang Y. (2017) “Structural basis for lipopolysaccharide extraction by ABC transporter LptB2FG”, Nat Struct Mol Biol, 24(5): 469-74.
  • Pace JB, Huang NN, Seguin JP, Esquina C, Olin E, Zhu G, Carr G. (2021) “Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System”, J Vis Exp, 10:178

Video at:

https://www.jove.com/v/63190/efficient-scalable-production-full-length-human-huntingtin-variants

Structural Biology Services Specialties

  • Integrated with Curia’s antibody/antibody-conjugate discovery, medicinal chemistry, computer-aided drug design (CADD), in vitro pharmacology and DMPK teams to provide complete Structure-Based Drug Development (SBDD) and Curia’s unique Structure-Driven Drug Development (SD3) solutions for both large (biologic) and small (synthetic) therapeutic molecule development.
  • Hit compound qualification for SBDD or SD3 by high-throughput protein crystallography.
  • High resolution structures of proteins or protein-ligand complexes by protein crystallography or cryo-EM.
  • Binding model development, testing and refinement by iterative cycles of ML/AI-mediated prediction, ligand synthesis and hypothesis test by high resolution protein-ligand structure determination.
  • A la carte option to combine the respective strengths of your own and Curia’s capabilities and experience.
  • Simple fee-for-service business models with no trailing obligations.
  • Absolute transparency, your scientists are able to talk directly to all members of the Curia team assigned to your program.
  • Experienced Project Management solutions are available up to and including management of multi-site, multi-disciplinary, international programs.

White paper

This white paper focuses on a few successful strategies used when growing crystals of challenging pharmaceutical targets to aid drug discovery. Included are two case studies performed by our experienced team of crystallographers at Curia.

Download

Ready to talk with our experts?

Contact Us